Cumulus Neuroscience and Muse by Interaxon have partnered to integrate at-home sleep EEG monitoring into the NeuLogiq platform, expanding the capabilities of Cumulus’ digital infrastructure for central nervous system (CNS) clinical trials. The collaboration adds objective measurements of brain activity during sleep to NeuLogiq’s existing suite of remote assessments, which already includes wake EEG, cognitive testing, mood tracking and speech analysis. The integrated solution is designed to help researchers collect richer neurological data from participants without requiring repeated visits to specialized sleep laboratories.
The partnership centers on Muse’s Muse S Athena headband, an at-home EEG device that measures sleep architecture by recording brain activity throughout the night. According to the companies, the system demonstrates high agreement with laboratory-based polysomnography while allowing participants to complete assessments in their own homes. By combining sleep EEG with other neurological and behavioral measures, researchers can capture continuous, longitudinal data that may provide deeper insight into disease progression and treatment response across conditions such as Alzheimer’s disease and other neurological disorders.
The companies believe the integration will help address longstanding challenges in CNS research, where clinical trials have often relied heavily on subjective assessments and infrequent clinic-based evaluations. By enabling scalable collection of objective brain-based measurements, the platform is intended to improve trial efficiency, reduce participant burden and support earlier decision-making during drug development. More broadly, the collaboration reflects growing momentum toward decentralized clinical trials and the use of wearable neurotechnology to bring high-quality brain monitoring into real-world settings.
Click here to read the original news story.
